224 related articles for article (PubMed ID: 17538173)
21. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
Siegel-Lakhai WS; Beijnen JH; Vervenne WL; Boot H; Keessen M; Versola M; Koch KM; Smith DA; Pandite L; Richel DJ; Schellens JH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4495-502. PubMed ID: 17671135
[TBL] [Abstract][Full Text] [Related]
22. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors.
Kalbakis K; Pappas P; Kouroussis C; Vamvakas L; Kalykaki A; Vardakis N; Nikolaidou M; Marselos M; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2008 Aug; 62(3):449-56. PubMed ID: 17960381
[TBL] [Abstract][Full Text] [Related]
23. A phase I and pharmacokinetic study of BAY59: a novel taxane.
Ramnath N; Hamm J; Schwartz G; Holden S; Eckhardt SG; Vredenburg MR; Bernacki RJ; Lathia C; Kanter P; Creaven PJ
Oncology; 2004; 67(2):123-9. PubMed ID: 15539916
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
25. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors.
Korfel A; Scheulen ME; Schmoll HJ; Gründel O; Harstrick A; Knoche M; Fels LM; Skorzec M; Bach F; Baumgart J; Sass G; Seeber S; Thiel E; Berdel WE
Clin Cancer Res; 1998 Nov; 4(11):2701-8. PubMed ID: 9829732
[TBL] [Abstract][Full Text] [Related]
26. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
Rasschaert M; Schrijvers D; Van den Brande J; Dyck J; Bosmans J; Merkle K; Vermorken JB
Anticancer Drugs; 2007 Jun; 18(5):587-95. PubMed ID: 17414628
[TBL] [Abstract][Full Text] [Related]
27. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674
[TBL] [Abstract][Full Text] [Related]
28. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design.
Gadgeel SM; Wozniak A; Boinpally RR; Wiegand R; Heilbrun LK; Jain V; Parchment R; Colevas D; Cohen MB; LoRusso PM
Clin Cancer Res; 2005 Sep; 11(17):6233-9. PubMed ID: 16144926
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.
Homsi J; Simon GR; Garrett CR; Springett G; De Conti R; Chiappori AA; Munster PN; Burton MK; Stromatt S; Allievi C; Angiuli P; Eisenfeld A; Sullivan DM; Daud AI
Clin Cancer Res; 2007 Oct; 13(19):5855-61. PubMed ID: 17908979
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of carboplatin (CBDCA) in children with cancer.
Bacha DM; Caparros-Sison B; Allen JA; Walker R; Tan CT
Cancer Treat Rep; 1986 Jul; 70(7):865-9. PubMed ID: 3521846
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma.
Raderer M; Wöhrer S; Bartsch R; Prager G; Drach J; Hejna M; Gaiger A; Turetschek K; Jaeger U; Streubel B; Zielinski CC
J Clin Oncol; 2005 Nov; 23(33):8442-6. PubMed ID: 16293875
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors.
Bomgaars LR; Megason GC; Pullen J; Langevin AM; Dale Weitman S; Hershon L; Kuhn JG; Bernstein M; Blaney SM
Pediatr Blood Cancer; 2006 Aug; 47(2):163-8. PubMed ID: 16317728
[TBL] [Abstract][Full Text] [Related]
33. Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors.
Lam CG; Furman WL; Wang C; Spunt SL; Wu J; Ivy P; Santana VM; McGregor LM
J Pediatr Hematol Oncol; 2015 Jan; 37(1):e13-8. PubMed ID: 24942022
[TBL] [Abstract][Full Text] [Related]
34. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
Awada A; Piccart MJ; Jones SF; Peck RA; Gil T; Lebwohl D; Wu CY; Burris HA
Cancer Chemother Pharmacol; 2009 Feb; 63(3):417-25. PubMed ID: 18446338
[TBL] [Abstract][Full Text] [Related]
35. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
Mita AC; Denis LJ; Rowinsky EK; Debono JS; Goetz AD; Ochoa L; Forouzesh B; Beeram M; Patnaik A; Molpus K; Semiond D; Besenval M; Tolcher AW
Clin Cancer Res; 2009 Jan; 15(2):723-30. PubMed ID: 19147780
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines.
Boku N; Ohtsu A; Hyodo I; Shirao K; Miyata Y; Nakagawa K; Tamura T; Hatake K; Tanigawara Y
Jpn J Clin Oncol; 2007 Jun; 37(6):440-5. PubMed ID: 17656482
[TBL] [Abstract][Full Text] [Related]
37. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer.
Zeh HJ; Brown CK; Holtzman MP; Egorin MJ; Holleran JL; Potter DM; Bartlett DL
Ann Surg Oncol; 2009 Feb; 16(2):385-94. PubMed ID: 19034580
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
Ten Bokkel Huinink WW; Sufliarsky J; Smit WM; Spanik S; Wagnerova M; Hirte HW; Kaye S; Johri AR; Oza AM
J Clin Oncol; 2009 Jul; 27(19):3097-103. PubMed ID: 19451434
[TBL] [Abstract][Full Text] [Related]
39. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
[TBL] [Abstract][Full Text] [Related]
40. Clinical pharmacokinetics of oxaliplatin: a critical review.
Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
